Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1.

Estève J, Blouin JM, Lalanne M, Azzi-Martin L, Dubus P, Bidet A, Harambat J, Llanas B, Moranvillier I, Bedel A, Moreau-Gaudry F, Richard E.

Stem Cell Res. 2019 May 21;38:101467. doi: 10.1016/j.scr.2019.101467. [Epub ahead of print]

2.

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia- dependent up-regulation of AXL.

Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart AV, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM.

Haematologica. 2019 Mar 28. pii: haematol.2018.205385. doi: 10.3324/haematol.2018.205385. [Epub ahead of print]

3.

Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.

Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, Escherich G, Feuchtinger T, Kosasih HJ, Khaw SL, Ekert PG, Pombo-de-Oliveira MS, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer RP, Fazio G, Cazzaniga G, Larghero P, Emerenciano M, Marschalek R.

Leukemia. 2019 Mar 21. doi: 10.1038/s41375-019-0451-7. [Epub ahead of print] No abstract available.

PMID:
30899083
4.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

5.

MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.

Dumas PY, Mansier O, Prouzet-Mauleon V, Koya J, Villacreces A, Brunet de la Grange P, Luque Paz D, Bidet A, Pasquet JM, Praloran V, Salin F, Kurokawa M, Mahon FX, Cardinaud B, Lippert E.

BMC Cancer. 2018 Nov 12;18(1):1098. doi: 10.1186/s12885-018-4993-2.

6.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
7.

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.

Calmettes C, Gabriel F, Blanchard E, Servant V, Bouchet S, Kabore N, Forcade E, Leroyer C, Bidet A, Latrabe V, Leguay T, Vigouroux S, Tabrizi R, Breilh D, Accoceberry I, de Lara MT, Pigneux A, Milpied N, Dumas PY.

Oncotarget. 2018 Jun 1;9(42):26724-26736. doi: 10.18632/oncotarget.25477. eCollection 2018 Jun 1.

8.

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.

Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon FX, Dulucq S, Etienne G.

Exp Hematol. 2018 Aug;64:97-105.e4. doi: 10.1016/j.exphem.2018.05.003. Epub 2018 May 23.

PMID:
29800673
9.

"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.

Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, Le Garff-Tavernier M, Bougacha N, Struski S, Bidet A, Laharanne E, Barin C, Veronese L, Prié N, Eclache V, Gaillard B, Michaux L, Lefebvre C, Gaillard JB, Terré C, Penther D, Bastard C, Nadal N, Fert-Ferrer S, Auger N, Godon C, Sutton L, Tournilhac O, Susin SA, Nguyen-Khac F; GroupeFrancophone de Cytogénétique Hématologique(GFCH) and the French Innovative Leukemia Organization (FILO) group.

Am J Hematol. 2018 Mar;93(3):375-382. doi: 10.1002/ajh.24990. Epub 2017 Dec 18.

10.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

11.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

12.

Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.

Gros FX, Cazaubiel T, Forcade E, Lechevalier N, Leguay T, Servant V, Tabrizi R, Clement L, Dumas PY, Bidet A, Pigneux A, Vigouroux S, Milpied N.

Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5. No abstract available.

PMID:
28581465
13.

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Bidet A, Chollet C, Gardembas M, Nicolini FE, Genet P, Delmer A, Caillot D, Dulucq S, Mahon FX, Lippert E.

Br J Haematol. 2018 Jul;182(1):148-152. doi: 10.1111/bjh.14748. Epub 2017 May 9. No abstract available.

PMID:
28485070
14.

Erratum to: BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.

Heiblig M, Bidet A, Callet-Bauchu E, Dumas PY, Chabane K, Salles G, Pigneux A.

Ann Hematol. 2017 Feb;96(2):337. doi: 10.1007/s00277-016-2879-4. No abstract available.

PMID:
27864605
15.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E.

Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3.

PMID:
27694926
16.

Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Luquet I, Bidet A, Cuccuini W, Lafage-Pochitaloff M, Mozziconacci MJ, Terré C.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):535-546. Review.

PMID:
27545007
17.

Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Bilhou-Nabéra C, Bidet A, Eclache V, Lippert E, Mozziconacci MJ.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):517-523. Review.

PMID:
27477946
18.

A case of acute promyelocytic leukaemia with unusual cytological features and a ZBTB16-RARA fusion gene.

Lechevalier N, Dulucq S, Bidet A.

Br J Haematol. 2016 Aug;174(4):502. doi: 10.1111/bjh.14198. Epub 2016 Jun 15. No abstract available.

PMID:
27302179
19.

Analysis of RUNX1 rearrangements: insights into leukaemogenesis mechanisms.

Bidet A, Laharanne E, Achard S, Migeon M, Moreau C, Lippert E.

Br J Haematol. 2016 Nov;175(4):738-740. doi: 10.1111/bjh.13881. Epub 2016 Jan 13. No abstract available.

PMID:
26765924
20.

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.

Mansier O, Migeon M, Etienne G, Bidet A, Lippert E.

Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4. No abstract available.

PMID:
26727159
21.

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

Mansier O, Migeon M, Saint-Lézer A, James C, Verger E, Robin M, Socié G, Bidet A, Mahon FX, Cassinat B, Lippert E.

J Mol Diagn. 2016 Jan;18(1):68-74. doi: 10.1016/j.jmoldx.2015.07.007. Epub 2015 Nov 18.

PMID:
26596525
22.

A novel cryptic insertion of CBFB into MYH11: importance of FISH probe design.

Bidet A, Laharanne E, Struski S, Luquet I, Lippert E.

Cancer Genet. 2014 Oct-Dec;207(10-12):516-7. doi: 10.1016/j.cancergen.2014.09.050. Epub 2014 Oct 5. No abstract available.

PMID:
25458460
23.

Transient abnormal myelopoiesis (TAM) in a neonate without Down syndrome.

Bidet A, Dulucq S, Aladjidi N.

Br J Haematol. 2015 Jan;168(1):2. doi: 10.1111/bjh.13166. Epub 2014 Oct 13. No abstract available.

PMID:
25308890
24.

ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?

Etienne G, Dulucq S, Lascaux A, Schmitt A, Bidet A, Fort MP, Lippert E, Bureau C, Adiko D, Hayette S, Reiffers J, Nicolini FE, Mahon FX.

Am J Hematol. 2015 Jan;90(1):37-41. doi: 10.1002/ajh.23864. Epub 2014 Oct 25.

25.

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.

Prebet T, Bertoli S, Delaunay J, Pigneux A, Delabesse E, Mozziconacci MJ, Bidet A, Recher C, Vey N.

Haematologica. 2014 Oct;99(10):e185-7. doi: 10.3324/haematol.2014.109827. Epub 2014 Jun 27. No abstract available.

26.

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

Dubois J, Etienne G, Laroche-Clary A, Lascaux A, Bidet A, Lippert E, Ait-ouferoukh S, Saada V, Micol JB, Bouabdallah K, Robert J.

Eur J Cancer. 2014 Jan;50(2):418-24. doi: 10.1016/j.ejca.2013.10.012. Epub 2013 Nov 14.

PMID:
24238921
27.

Clinical characteristics and laboratory testing of patients with suspected HIT: a survey on current practice in 11 university hospitals in France.

Bidet A, Tardy Poncet B, Desprez D, de Maistre E, Presles E, Lecompte T, Lavenu-Bombled C, Huisse MG, Wolf M, Morange P, Racadot E, Mouton C, Grunebaum L, Pouplard C, Tardy B; GEHT-HIT study group.

Thromb Res. 2010 Jun;125(6):e294-9. doi: 10.1016/j.thromres.2010.02.003. Epub 2010 Feb 23.

PMID:
20181380
28.

VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.

Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P.

Platelets. 2010;21(2):94-100. doi: 10.3109/09537100903437206.

PMID:
20148735
29.

[Acquired and repeated factor VII deficiency during two infectious episodes: a case report].

Bidet A, Boiteux-Vergnes C, Mouton C.

Ann Biol Clin (Paris). 2009 Sep-Oct;67(5):587-9. doi: 10.1684/abc.2009.0370. French.

30.

Therapeutic education unit for heart failure: setting-up and difficulties. Initial evaluation of the I-CARE programme.

Juillière Y, Jourdain P, Roncalli J, Boireau A, Guibert H, Lambert H, Spinazze L, Jondeau G, Sonnier P, Rouanne C, Bidet A, Sandrin-Berthon B, Trochu JN; I-CARE participants of the Working Group on Heart Failure of the French Society of Cardiology.

Arch Cardiovasc Dis. 2009 Jan;102(1):19-27. doi: 10.1016/j.acvd.2008.10.015. Epub 2009 Jan 30.

31.

[Clinical value of the blood measurement of the free light chains of immunoglobulins].

Bidet A, Marit G, Bérard AM.

Ann Biol Clin (Paris). 2008 Jul-Aug;66(4):427-31. doi: 10.1684/abc.2008.0250. French.

32.

[Research of 99mTcO4- and 99mTcO2- in injectable solutions of 99mTc-HMDP by inverse phase HPTLC].

Jacquot Y, Zoubir B, Xicluna A, Bidet AC.

Ann Pharm Fr. 2006 Jan;64(1):63-7. French.

PMID:
16449940
33.

Parathyroid adenoma visualization on octreotide scintigraphy.

Boulahdour H, Bertrand AM, Klingelschmitt S, Rudenko B, Loboguerrero A, Bidet AC, Mantion G, Cardot JC.

Clin Nucl Med. 2002 Apr;27(4):304-5. No abstract available.

PMID:
11914679
34.

Intestinal permeability in patients with psoriasis.

Humbert P, Bidet A, Treffel P, Drobacheff C, Agache P.

J Dermatol Sci. 1991 Jul;2(4):324-6.

PMID:
1911568
35.

Intestinal permeability in ankylosing spondylitis.

Wendling D, Bidet A, Guidet M.

J Rheumatol. 1990 Jan;17(1):114-5. No abstract available.

PMID:
2313660
36.

[Evaluation of intestinal permeability in ankylosing spondylarthritis with a test using Cr-EDTA].

Wendling D, Bidet A, Guidet M.

Rev Rhum Mal Osteoartic. 1990 Jan;57(1):29-32. French. No abstract available.

PMID:
2108485
37.

Diagnosis of splenosis: the advantages of splenic scintiscanning with Tc 99m heat-damaged red blood cells.

Bidet AC, Dreyfus-Schmidt G, Mas J, Combe J, Milleret P, Bidet R.

Eur J Nucl Med. 1986;12(7):357-8.

PMID:
3792367
38.

[Determination of ventricular volumes by a non-geometric method using gamma-cineangiography].

Faivre R, Cardot JC, Baud M, Verdenet J, Berthout P, Bidet AC, Bassand JP, Maurat JP.

Arch Mal Coeur Vaiss. 1985 Aug;78(8):1181-7. French.

PMID:
3935075
39.

Factors influencing the quantification of valvular regurgitation by gated equilibrium radionuclide angiography.

Berthout P, Cardot JC, Baud M, Faivre R, Verdenet J, Bidet AC, Bassand JP, Bidet R, Maurat JP.

Eur J Nucl Med. 1984;9(3):112-4.

PMID:
6609074
40.

A computer program for compression of dynamic studies.

Verdenet J, Cardot JC, Baud M, Bidet AC, Duvernoy J, Bazin R, Bidet R.

Comput Programs Biomed. 1983 Feb-Apr;16(1-2):77-82. No abstract available.

PMID:
6687859
41.

Temporal Fourier analysis applied to equilibrium radionuclide cineangiography. Importance in the study of global and regional left ventricular wall motion.

Cardot JC, Berthout P, Verdenet J, Bidet A, Faivre R, Bassand JP, Bidet R, Maurat JP.

Eur J Nucl Med. 1982;7(8):353-8.

PMID:
7117278
42.

Preservation of human erythrocytes in the liquid state: biological results with a new medium.

Herve P, Lamy B, Peters A, Toubin M, Bidet AC.

Vox Sang. 1980 Oct;39(4):195-204.

PMID:
7210608
43.

[Method of cryopreservation of platelets at - 196 degrees C. Clinical application].

Herve P, Masse M, Potron G, Kieffer Y, Carbillet JP, Bidet A, Bosset JF, Peters A.

Rev Fr Transfus Immunohematol. 1977 Dec;20(4):603-15. French. No abstract available.

PMID:
601402

Supplemental Content

Support Center